The FDA has approved Merck’s 21-valent pneumococcal vaccine, which is specifically made for adults, the company announced. News News CME CME ...

The Food and Drug Administration (FDA) has approved pharmaceutical company Merck’s (NYSE:MRK) new vaccine, Capvaxive. This pneumococcal conjugate vaccine is designed to prevent invasive disease ...

The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia.

FDA Approves Merck's Vaccine For Adult Invasive Pneumococcal Disease Provided by Dow Jones Jun 17, 2024, 10:05:00 PM. By Emon Reiser . The Food and Drug Administration approved Merck's Capvaxive ...

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...

Merck's vaccine, branded Capvaxive, helped produce an immune response against all 21 serotypes, ... US FDA approves Merck's pneumococcal vaccine for adults. June 17, 2024 at 5:52 PM.